Bentley's generic Prozac approved in Spain
Two wholly-owned Spanish subsidiaries of US generics firm BentleyPharmaceuticals, Laboratorios Belmac and Laboratorios Davur, have been granted approval by the Spanish Ministry of Health to market generic versions of Eli Lilly's antidepressant Prozac (fluoxetine). The subsidiaries plan to launch their generic versions of the drug in the fourth quarter of this year. Bentley estimates that the Spanish market for antidepressants is currently valued at around $267 million, with a growth rate of 16% and with fluoxetine accounting for 25% of the total market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze